Trial Profile
A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs Leflunomide (Primary) ; Prednisone
- Indications Autoimmune disorders
- Focus Therapeutic Use
- 15 Jun 2019 Results assessing efficacy of leflunomide in combination with glucocorticoids in patients with IgG4-related disease, presented at the 20th Annual Congress of the European League Against Rheumatism.
- 04 Mar 2019 Status changed from not yet recruiting to completed.
- 14 Mar 2016 New trial record